

See discussions, stats, and author profiles for this publication at: <https://www.researchgate.net/publication/10599902>

Identification and characterization of novel components of a Ca^{2+} /calmodulin-dependent protein kinase cascade in HeLa cells

ARTICLE in FEBS LETTERS · SEPTEMBER 2003

Impact Factor: 3.17 · DOI: 10.1016/S0014-5793(03)00817-2 · Source: PubMed

CITATIONS

19

READS

34

6 AUTHORS, INCLUDING:



Hiroshi Tokumitsu

Okayama University, Okayama, Japan

100 PUBLICATIONS 4,024 CITATIONS

SEE PROFILE



Hiroyuki Inuzuka

Harvard Medical School

64 PUBLICATIONS 1,942 CITATIONS

SEE PROFILE

Identification and characterization of novel components of a Ca^{2+} /calmodulin-dependent protein kinase cascade in HeLa cells

Yumi Ishikawa^a, Hiroshi Tokumitsu^{a,*}, Hiroyuki Inuzuka^a, Maki Murata-Hori^b,
Hiroshi Hosoya^b, Ryoji Kobayashi^a

^aDepartment of Signal Transduction Sciences, Kagawa Medical University, 1750-1 Miki-cho, Kita-gun, Kagawa 761-0793, Japan

^bDepartment of Biological Science, Graduate School of Science, Hiroshima University, Higashi-Hiroshima 739-8526, Japan

Received 28 May 2003; revised 14 July 2003; accepted 15 July 2003

First published online 29 July 2003

Edited by Judit Ovádi

Abstract In this report, we cloned a novel calmodulin-kinase (CaM-KI δ) from HeLa cells and characterized its activation mechanism. CaM-KI δ exhibits Ca^{2+} /CaM-dependent activity that is enhanced (~ 30 -fold) in vitro by phosphorylation of its Thr180 by CaM-K kinase (CaM-KK) α , consistent with detection of CaM-KI δ -activating activity in HeLa cells. We also identified a novel CaM-KK β isoform (CaM-KK β -3) in HeLa cells whose activity was highly Ca^{2+} /CaM-independent. Transiently expressed CaM-KI δ exhibited enhanced protein kinase activity in HeLa cells without ionomycin stimulation. This sustained activation of CaM-KI δ was completely abolished by Thr180Ala mutation and inhibited by CaM-KK inhibitor, STO-609, indicating a functional CaM-KK/CaM-KI δ cascade in HeLa cells.

© 2003 Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies.

Key words: Ca^{2+} ; CaM-kinase cascade; CaM-kinase δ ; CaM-K kinase

1. Introduction

Ca^{2+} /calmodulin-dependent protein kinases (CaM-Ks) are implicated in the regulation of wide variety of biological events that are mediated by intracellular Ca^{2+} including muscle contraction, neurotransmitter release, and gene expression. Recent studies have demonstrated that two multifunctional CaM-Ks, CaM-KI and IV are themselves activated by the phosphorylation of a Thr residue in their activation loop by an upstream CaM-K kinase (CaM-KK). This constitutes a novel Ca^{2+} -signal transduction pathway, CaM-K cascade (reviewed in [1,2]). Two CaM-KK genes, CaM-KK α and CaM-KK β , have been cloned in mammals and homologues have been found in *Caenorhabditis elegans* and *Aspergillus nidulans* [3–8].

It has been shown that CaM-KI is activated in response to elevation of intracellular Ca^{2+} mediated by membrane depolarization in PC12 cells through phosphorylation by CaM-KK [9]. We have also demonstrated that the CaM-KK mediated activation of CaM-KI in *C. elegans* results in induction of

CREB-dependent transcription in transfected cells and in living nematode [10,11]. Recently, Suizu et al. reported that the activation of CaM-KK/CaM-KI cascade induces myosin II phosphorylation at Ser19, resulting in regulation of actin filament organization in mammalian cells [12]. However, the various physiological function(s) mediated by the mammalian CaM-KK/CaM-KI cascade and the CaM-KK involved in regulating CaM-KI activity in vivo are not well understood.

In further characterizing CaM-KK/CaM-K cascade, we report here the cloning of a novel human CaM-KI isozyme (CaM-KI δ) as well as a novel isoform of CaM-KK β in HeLa cells. Furthermore, we characterized the activation of CaM-KI δ through phosphorylation by CaM-KK isoforms in vitro and in transfected cells.

2. Materials and methods

2.1. Cloning of CaM-KI δ and CaM-KK β -3

The method used to clone of CaM-KI δ has been previously reported [13]. Briefly, a HeLa cDNA library in the λ ZAPII vector was screened with a 1.0 kbp *SalI/HindIII* fragment derived from bovine stomach MLCK (pSL17) under low stringency conditions, and then the positive clone was subcloned into pBluescript SK(–). Cloning of CaM-KK β -3 was performed by RT-PCR using random hexamer-primed cDNA prepared from HeLa cells as a template and specific primers for human CaM-KK β -1 (sense primer, 5'-CCAGTGTGCTGGATGAAGCTGGCGCATGC-3'; antisense primer, 5'-CACACGTGCTGGGTTCCGTAGGACATGCT-3'; nested primer, 5'-CTATGGAAACGCGGTGCGAGCAGCCCCCAG-3', [15]). The first PCR was carried out using the sense and the antisense primers followed by the second PCR using the nested antisense primer. A 1.8 kbp PCR fragment contained a 1827 bp clone (CaM-KK β -3) and a 1698 bp clone (CaM-KK β -3x). The nucleotide sequence data reported in this paper appear in the DDBJ, EMBL and GenBank nucleotide sequence databases under the accession number AB081726 (CaM-KI δ), AB081336 (CaM-KK β -3) and AB081337 (CaM-KK β -3x).

2.2. Construction and purification of recombinant CaM-KI δ and CaM-KK β -3

CaM-KI δ cDNA was amplified by PCR using the sense primer, 5'-GCTCTAGAGATGGCCGGGAGAACGGCGAG-3' and the antisense primer, 5'-CCGCTCGAGTCAGCTGAGGGATTCTGG-3' and then ligated into the *XbaI/XhoI* sites of the pGEX-KG-PreS vector [14]. The Thr180Ala mutant of CaM-KI δ was created by site-directed mutagenesis using a mutagenic oligonucleotide (5'-AGTTC-CACAGGCAGCGGACATCAGATCTCC-3'). GST-CaM-KI δ s were expressed in the *Escherichia coli* JM-109 by induction with 1 mM IPTG and purified by glutathione-Sepharose column chromatography. The cDNA of CaM-KK β -3 was introduced into pET-16b (Novagen). Recombinant CaM-KK β -3 was expressed in the *E. coli* strain BL-21 (DE3) and purified by ProBond[®] nickel-chelating resin (Invi-

*Corresponding author. Fax: (81)-87-891 2368.

E-mail address: tokumit@kms.ac.jp (H. Tokumitsu).

Abbreviations: CaM-K, Ca^{2+} /calmodulin-dependent protein kinase; HA, hemagglutinin

A

CGGCGCGCGCGCGCGCGAGAGTCTGTGCCCCGAGAACAGCAGAAATAAGAGCCAGGGAG
 GGACCGCGCGCGCGCGCGCGCGAGAGCGAGAGGAAAGTGCAGAGGAGGAAAGCTG
 CGCGCAGCGCGAGCGCGCGCGCATCCCCGCGCGCTCTGCGCGCGCGCGCGCGCGCGCG
 GCCCCTCCCCAGCGCGCGCGCGCGCGCTCTCTCGCGCGCGCGCTCTGCGCGCATGGCCCG 8
 M A R
 GGAGAAGCGCGAGGAGCAGCTCTCTGGAAGGCAAGCTGAAGACATCAAGAAGATCTT 68
 E N G E S S S S S W K K Q A E D I K K I F
 CGAGTTCAGAGAGACCTCGGAACCGGGGCTTTTCCGAAGTGGTTTAGCTGAAGAGAA 128
 E F K E T L G T G A F S E V V L A E E K
 GGCAACTGGCAAGCTCTTTGCTGTGAAGTGTATCCCTAAGAAGCGCTGAAGGCAAGGA 188
 A T G K L F A V K C I P K K A L K G K E
 AAGCAGCATAGAGATGAGATAGCCGCTCTGAGAAAGATTAAGCATGAAATATTTGTTG 248
 S S I E N E I A V L R K I K H E N I V A
 CCTGGAAGACATTATGAAAGCCCAATCAGCTGTACTTGGTCATGCACTGGTGTCCGG 308
 L E D I Y E S P N H L Y L V M Q L V S G
 TGGAGAGCTTTTGACCGGATAGTGGAGAAGGGTTTATACAGAGAAGGATGCCAGCAC 368
 G E L F D R I V E K G F Y T E K D A S T
 TCTGATCCGCCAAGTCTTGGACGCGGTGTACTATCTCCACAGATGGGCATCGTCCACAG 428
 L I R Q V L D A V Y Y L H R M G I V H R
 AGACCTCAAGCGGAAATCTTGTACTACAGTCAAGATGAGGAGTCCAAATAATGAT 488
 D L K P E N L L Y Y S Q D E E S K I M I
 CAGTGACTTTGGATTGCAAAATGGAGGGCAAGGAGATGTGATGTCCACTGCTGTGG 548
 S D F G L S K M E G K G D V M S T A C G
 AACTCCAGGCTATGTGCTGCTGAGTCTCGCCGAGAAACCTTACAGCAAGCCGTTGA 608
 T P G Y V A P E V L A Q K P Y S K A V D
 CTGCTGGTCCATCGGAGTGATTGCTTACATCTGCTCTGCGGCTACCCCTCTTTTATGA 668
 C W S I G V I A Y I L L C G Y P P F Y D
 TGAAATGACTCAAGCTCTTGTGAGCATCTCAAGCGGAATATGAGTTGACTCTCC 728
 E N D S K L F E Q I L K A E Y E F D S P
 CTACTGGGATGACATCTCGGACTCTGCAAAAGACTTTCAGGAACCTGATGGAGAGGA 788
 Y W D D I S D S A K D F I R N L M E K D
 CCCGAATAAAGATACACGTGTGAGCAGGAGCTCGGCACCCATGGATCGCTGGTGACAC 848
 P N K R Y T C E Q A A R H P W I A G D T
 AGCCCTCAACAAAAACATCCACGAGTCCGCTCAGCGCCAGATCCGGAAGAACTTTGCCAA 908
 A L N K N I H E S V S A Q I R K N F A K
 GAGCAATGGAGACAAGCATTTAATGCCACGCGCTGCTGAGACATATGAGAAATACATA 968
 S K W R Q A F N A T A V V R H M R K L H
 CCTCGGAGCAGCTGGACAGTTCAAATGCAAGTGTTCGAGCAGCTCAGTTTGCCAG 1028
 L G S S L D S S N A S V S S S L S L A S
 CCAAAAGACTGTCTGGCAGCTTCCAGCTCTGTAGTTTCATTCTCTCTCGTGGGGGT 1088
 Q K D C L A P S T L C S F I S S S S G V
 CTCAGGAGTTGGAGCGAGCGGAGACCCAGGCCACCACTGTGACGCGAGTGCACCTGG 1148
 S G V G A E R R P R P T T V T A V H S G
 AAGCAAGTGACTGGCCCTGGAGGTGGGCGCGGGTCTGGGGCTGGGAAGGGGAGCCCA 1208
 S K *
 GGGTCGCCAGTGCAGCGAGCCACTCCAGCGAGACCCACCTTGCATGGTGCCTTCTCTG
 CATAGGACTGGAAGACCGAAGTTTTTTATGGCCATATTTCTACTGCAATTCGTAAGTG
 TTCATTTCTCAAACTGTACTGACTCGAGGGCGCTGATTTTCATAGGATCTGGTGTCTG
 ATATACGAATCTTGAAGCTCTAAGTGAACGAGCTCTTATTCCTCTCCCTAACACC
 ATCGTTTCCACTCTTCTAGTGTAGGTAAACGCTCTATGGTGTGTTTTTCTATTAATGACA
 AAAAAAAGGTTTCACTGGATTATTTAAATATTGGTAAATATTGTGCATTAGGGTTT
 GTTTTCTCTTTAAGAAAGTATGTCCTTTCTATCTCTAAGTACATGACCTATATCTTTTC
 CTCCTTTAATAGTAGTTTATGTTAACCCTTTAAGAGATTGTTTTCTCTCAAGGAGAAAT
 TAAAGGTATTTTTTAAATTTCAATAAGAGGATCAGCGGGTGCATGACTCATGCTGT
 AATCCAGCACGTTGGGAGGCCAAGTCGGGCGGATCACAAAGTCAAGGATCAAGGCCAT
 CCTGGCCAAATGGTGAACCCACGCTACTAATAAATACAAAAATTAGCGGGCGTGG
 TGGCACACCTGTAGTCCCGCTACTCGGGAGGCTGAGGCAGGAGAAATGCTTGAACCC
 GGGAGACGAGGTTGAGTGTGAGATGCTGCCATGCACTCCAGCTGGGTGACAGA
 CCAAGACTCTGTCTC

B

Catalytic Domain			
human CaM-KIδ	1:	MARENGESSSSWKKQAEIDKKIFEFKETLTGTGAFSEVVLAEKATGKLFVAVKCIPIKKALK	60
human CKLiK	1:	-----	60
human CaM-KIα	1:	ML GAV- GPR- ----RD-YD-RDV-----I---D-R-Q--V-I---A-E--E	57
human CaM-KIδ	61:	GKESSIENEIAVLRKIKHENIVALEDIYESPNHLYVMQLVSGGELFDRIEKGFTYKED	120
human CKLiK	61:	-----	120
human CaM-KIα	58:	---G-M-----H---P-----D---GG---I-----R-	117
human CaM-KIδ	121:	ASTLIQVLDVAVYLYHRMGIHVRLDKPENLLYSQDEESKIMISDFGLSKMEGKGDVMS*	180
human CKLiK	121:	-----	180
human CaM-KIα	118:	--R--F-----K--DL-----L--D-----DP-S-L--	177
human CaM-KIδ	181:	ACGTPGYVAPEVLAQKPYSKAVDCWSIGVIAYILLCGYPFYDENDSKLFEQILKAEYEF	240
human CKLiK	181:	-----	240
human CaM-KIα	178:	-----A-----	237
human CaM-KIδ	241:	DSPIWDDISDSAKDFIRNLMKEDPNKRYTCEQAARHPWIAAGDTALNKNIHESVSAQIRKN	300
human CKLiK	241:	-----	300
human CaM-KIα	238:	-----H-----E--F-----LQ-----D---Q---E--K--	297
Regulatory Domain			
human CaM-KIδ	301:	FAKSKWRQAFNATAVVRHMRKLHLGSSSLDSSNASVSSSLSLASQKDLAPSTLCFSISS	360
human CKLiK	301:	-----AYVAKPE-LS	357
human CaM-KIα	298:	-----K-----Q--T-QEGQGQTA-HGEL-TPVAGGP-AGCC-RDCCVE	357
human CaM-KIδ	361:	SGVSGVGAERRPRPTTAVHSGSK	385
human CKLiK			
human CaM-KIα	358:	P-TELSPTLPHQL	370

C




Fig. 1. Cloning and mRNA expression pattern of human CaM-KIδ. A: Nucleotide and deduced amino acid sequence of human CaM-KIδ. B: Comparison of amino acid sequences of human CaM-KIδ, human CKLiK [20] and human CaM-KIα. Residues identical to human CaM-KIδ are indicated with a dash and gaps in the alignment are indicated with a space. An asterisk indicates the Thr180 residue in the activation loop. A catalytic domain is indicated with a box. A putative regulatory domain including autoinhibitory and CaM-binding regions is indicated with a dot. C: RT-PCR analysis for human CaM-KIδ was performed using specific primers (underlined sequences in panel A) with cDNAs from HeLa cells (right panel) and human tissues (left panel). RT-PCR for G3PDH (lower panel) was performed as a control experiment. M, 100 bp DNA ladder marker.

trogen) followed by CaM-Sepharose chromatography according to the manufacturer's protocol.

2.3. RT-PCR analysis

RT-PCR analysis of CaM-KI δ was performed with multiple human tissue cDNA panels (Clontech) using 5'-CATGGATCGCTGGTGA-CACAGCCCTCAACA-3', and 5'-GGCCAGTCACTTGCTTCCAGAGTGCAGTGC-3' as primers (Fig. 1A). PCR reaction was carried out according to the manufacturer's protocol using TITANIUM[®] Taq DNA polymerase (Clontech).

2.4. Activation and phosphorylation of CaM-KI δ in vitro

Either purified recombinant CaM-KK α (2.8 μ g/ml [14]) or HeLa cell extract (0.5 mg/ml) was incubated with either 1.8 μ g GST-CaM-KI δ or the Thr180Ala mutant at 30°C for 10 min in a solution (10 μ l) containing 50 mM HEPES (pH 7.5), 10 mM Mg(Ac)₂, 1 mM DTT, either 200 μ M ATP or 100 μ M [γ -³²P]ATP in the presence of either 1 mM EGTA or 1 mM CaCl₂/10 μ M CaM with 1 μ M microcystin LR (for treatment with HeLa cell extract). The reaction was initiated by the addition of ATP and terminated by addition of SDS-PAGE sample buffer and then analyzed by SDS-PAGE followed by autoradiography or terminated by dilution with 200 μ l of 50 mM HEPES, pH 7.5, 2 mg/ml bovine serum albumin, 10% ethylene glycol, and 1 mM EDTA. Five μ l of the diluted sample (43 ng of CaM-KI δ) was then subjected to the protein kinase assay. CaM-KI δ activity was measured at 30°C for 5 min using 40 μ M syntide-2 as a substrate and 100 μ M [γ -³²P]ATP (1000–2000 cpm/pmol) in the presence of either 1 mM EGTA or 1 mM CaCl₂/2 μ M CaM as previously described [16]. Results represent the mean and standard error of the mean (S.E.M.) of three experiments.

2.5. Transient expression and immunoprecipitation of hemagglutinin (HA)-CaM-KI δ and HA-CaM-KIV

Either HA-CaM-KI δ or HA-CaM-KIV (2 μ g) was transfected into HeLa and COS-7 cells with or without 1.5 μ g CaM-KK β -3-expressing plasmid DNA and 20 μ g LipofectAMINE Reagent (Invitrogen) in 2.5 ml medium as previously described [17]. After 20 h incubation, the cells were further cultured in serum-free medium for 6 h and then treated with or without 1 μ M ionomycin for 5 min. Stimulation was terminated by the addition of 1 ml of lysis buffer and then HA-tagged kinases were immunoprecipitated with 4 μ g of anti-HA antibody (clone 12CA5, Roche Molecular Biochemicals) followed by measurement of protein kinase activity in the presence of 100 μ M [γ -³²P]ATP, 1 mM CaCl₂/2 μ M CaM (or 1 mM EGTA for HA-CaM-KI δ 1-296)

and 10 μ g/ml STO-609 [17] using 40 μ M syntide-2 as a substrate at 30°C for 5 min [18]. Results represent the mean and S.E.M. of three independent transfections.

2.6. CaM-KK activity assay

Activity of recombinant human CaM-KK β -3, CaM-KK β -3x or rat CaM-KK α was measured by using 10 μ g GST-CaM-KI1-293, K49E as a substrate and 100 μ M [γ -³²P]ATP in the presence of either 1 mM EGTA or 1 mM CaCl₂/2 μ M CaM at 30°C for 5 min [19].

3. Results and discussion

A HeLa cDNA library was screened under low stringency conditions with a partial cDNA fragment derived from bovine MLCK that contains both the catalytic and regulatory domains [13]. This allowed us to isolate a 2235 bp clone encoding a stretch of 385 amino acid residues (Fig. 1A) that shares considerable homology with human CaM-KI (80% identity) and that is strikingly similar to a CaM-KI like kinase (CKLiK) that was originally identified as a granulocyte-specific kinase [20] (Fig. 1B). It has been suggested that CKLiK may play a role in transducing chemokine-induced signals regulating human granulocyte functions [20]. Alignment of the deduced amino acid sequences and the nucleotide sequences (data not shown) of both protein kinases reveals that their catalytic domains and their putative regulatory domains, including the CaM-binding site, are completely identical (Fig. 1B). However, their C-terminal tail regions after Cys347 differed. This sequence homology suggests that the CaM-dependent kinase clone identified by our screening is likely a C-terminal alternative spliced isoform of CKLiK. Based on the structural similarity to CaM-KI family, we tentatively termed the isolated clone as CaM-KI δ . RT-PCR analysis reveals that in addition to HeLa cells, CaM-KI δ possesses a widespread tissue distribution but expressed very weak or undetectable levels in the heart, placenta and kidney (Fig. 1C).




Fig. 2. Activation and phosphorylation of CaM-KI δ in vitro. A: Activation of CaM-KI δ by CaM-KK α . Either GST-CaM-KI δ wild-type (WT) or Thr180Ala mutant (T180A) was incubated with (+) or without (-) purified recombinant CaM-KK α at 30°C for 10 min with 200 μ M ATP in the presence of either 1 mM EGTA (-) or 1 mM CaCl₂/10 μ M CaM (+). After terminating the reaction, GST-CaM-KI δ was subjected to the protein kinase assay as described in Section 2 in the either presence of 1 mM EGTA (open bar) or 1 mM CaCl₂/2 μ M CaM (closed bar). B: Phosphorylation of either GST-CaM-KI δ wild-type (WT) or Thr180Ala mutant (T180A) by CaM-KK α was analyzed by SDS-15% PAGE followed by autoradiography. C: Activation of CaM-KI δ by HeLa cell extract. Either GST-CaM-KI δ wild-type (WT) or Thr180Ala mutant (T180A) was incubated with (+) or without (-) HeLa cell extract (0.5 mg/ml) and then subjected to the protein kinase assay.




Fig. 3. Activation of CaM-KI δ in transfected HeLa cells. A,B: HeLa cells were transfected with either empty vector (Mock), HA-CaM-KI δ -expressing vector (A) or HA-CaM-KIV-expressing vector (B). After 20 h incubation, the cells were further cultured in serum-free medium for 6 h and then treated with (+) or without (-) 1 μ M ionomycin for 5 min and then immunoprecipitated samples were subjected to protein kinase assay in the presence of 1 mM CaCl₂/2 μ M CaM and 10 μ g/ml STO-609 [17] as described in Section 2. Immunoprecipitated samples (1/5 vol.) were subjected to CaM-overlay in the presence of 1 mM CaCl₂ (inset). Arrows indicate HA-CaM-KI δ (A) and HA-CaM-KIV (B). C,D: Effect of CaM-KK inhibitor, STO-609 on the activation of CaM-KI δ in HeLa cells. HeLa cells were transfected with either empty vector (Mock), HA-CaM-KI δ -expressing vector (C) or HA-CaM-KI δ 1-296-expressing vector (D) and then cultured for 20 h either with (+) or without (-) 10 μ g/ml STO-609 followed by culturing in serum-free medium for 6 h either with (+) or without (-) 10 μ g/ml STO-609. After treatment with (+) or without (-) 1 μ M ionomycin for 5 min (D) or no treatment (C), the cells were lysed and immunoprecipitated samples were subjected to protein kinase assay as described above. Immunoprecipitated samples (1/5 vol.) were subjected to either CaM-overlay as described above (C inset) or Western blotting analysis using anti-HA antibody (D inset).

This result indicates that CaM-KI δ may play a role in Ca²⁺-mediated regulation of the functions of various cells.

Since the activation loop of CaM-KI δ contains the Thr180 residue involved in kinase activation (Fig. 1B), we assessed whether the kinase activity of CaM-KI δ could be activated by a CaM-KK in vitro by using purified GST-fused CaM-KI δ . In the absence of CaM-KK α , CaM-KI δ exhibited Ca²⁺/CaM-dependent kinase activity (34.5 ± 2.0 nmol/min/mg) (Fig. 2A). This activity was elevated approximately 30-

fold (979.2 ± 43.4 nmol/min/mg) by treatment with CaM-KK α in a Ca²⁺/CaM-dependent manner (Fig. 2A), which was associated with Thr180 phosphorylation by CaM-KK α (Fig. 2B). Thus CaM-KK α can phosphorylate Thr180 in CaM-KI δ , resulting in a large induction of its catalytic efficiency. Whereas we observed Ca²⁺/CaM-dependent autophosphorylation of CaM-KI δ , it had no impact on CaM-KI δ activity (Fig. 2A,B).

In agreement with in vitro activation of CaM-KI δ as shown in Fig. 2A, we found that HeLa cell extract can activate CaM-

A

```

-32  CCAGTGTGCTGGAGGAAGCTGGCGCATGCACC
ATGTCATCATGTGCTCTAGCCAGCCAGCAGCAACCGGCGCGCCCGCCAGGATGAGCTG  60
M S S C V S S S Q P S S N R A A P Q D E L
GGGGGCGGGGCGAGCAGCAGCAGCAAGCCCTGTAGGCGCTCGGGGCGCTC  120
G G R G S S S S S E S Q K P C E A L R G L
TCATCCTTGAGCATCCACTGGGCATGGAGTCTTCATGTGTGTCACGAGTGTGAGCG  180
S S L S I H L G M E S F I V V T E C E P
GGGTGTGTGTGGACCTCGGCTTGGCGCGGACCGGCGCTGGAGGCGATGGCCAGAG  240
G C A V D L G L A R D R P L E A D G Q E
GTCCCTTGTACACCTCCGGGTCCAGGCGCGGCGCCACCTCTCCGGTCGCAAGCTGTCT  300
V P L D T S G S Q A R P H L S G R K L S
CTCAAGAGCGGTCCAGGGTGGGCTGGCAGCGGTGGCAGCTGGACATGAACGAGCG  360
L Q E R S Q G G L A A G G S L D M N G R
TGCATCTGCCGTCCTGCCCTACTCACCGTCAGTCCCGCAGTCTCGCTCGGCTG  420
C I C P S L P Y S P V S P Q S S P R L
CCCCGGCGCGCAGTGGAGTCTCACCACTCTCCATCAGGGATGCGAGGACTGTGTG  480
P R R P T V E S H H V S I T G M Q D C V
CAGCTGAATCAGTATACCTGAAGGATGAATTTGAAAGGGCTCCTATGGTGTGCTCAAG  540
Q L N Q Y T L K D E I G K G S Y G V V K
TTGGCTTACAATGAAATGACAATACCTACTATGCAATGAAGGTGTGTCTCAAAAGAG  600
L A Y N E N D N T Y Y A M K V L S K K K
CTGATCCGGCAGGCGGCTTCCACGTCCGCTCCACCCGAGGCGCCGCGCAGCTCCT  660
L I R Q A G F P R R P P P R G T R P A P
GGAGGTGCTATCCAGCCAGGGCGCCATTGAGCAGGTGTACAGGAATTCGCATCCTC  720
G G C I Q P R G P I E Q V Y Q E T A I L
AAGAAGCTGGACACCCCAATGTGGTGAAGTGGTGGAGTCTGGATGACCCCAATGAG  780
K K L D H P N V V K L V E V L D D P N E
GACCATCTGTACATGTGTGCTGAAGTGTCAACCAAGGCGCGTGTGATGGAGTCCAC  840
D H L Y M V F E L V N Q G P V M E V P T
CTCAAAACCATCTCTGAAGACCGAGGCGGCTTCTACTTCCAGGATCTGATCAAGGCAT  900
L K P L S E D Q A R F Y F Q D L I K G I
GAGTACTTACACTACCAGAAGATCATCCACGTGACATCAAACTTCAACCTCTCGGTC  960
E Y L H Y Q K I I H R D I K P S N L L V
GGAGAAGATGGGCACATCAAGATCGTGACTTGGTGTGAGCAATGAATCAAGGCGAGT  1020
G E D G H I K I A D F G V S N E F K G S
GACGCGCTCTCTCCCAACCGTGGGCACGCGCGCTTCTATGGCAGCGGAGTGTGCTCT  1080
D A L L S N T V G T P A F M A P E S L S
GAGACCCGCAAGATCTTCTCTGGGAAGCGCTTGGATGTTTGGGCACTGGGTGTGAC  1140
E T R K I F S G K A L D V W A M G V T L
TACTGCTTTGTCTTGGCCAGTGCCTATTCATGGAGCAGCGGATCATGTGTTACACAGT  1200
Y C F V F G Q C P F M D E R I M C L H S
AAGATCAAGAGTCAGGCGCTGGAATTTCCAGACCGCGGACATAGCTGAGGACTTGAAG  1260
K I K S Q A L E F P D Q P D I A E D L K
GACCTGATCACCCGTATGCTGGACAAGACCCGAGTCGAGGATCGTGGTCCGCGAATC  1320
D L I T R M L D K N P E S R I V V P E I
AAGCTGCACCCCTGGGTACGAGGATGGGGCGGAGCGCTTGGCGTCGGAGGATGAGAAC  1380
K L H P W V T R H G A E P L P S E D E N
TGCACGCTGGTCAAGTGAAGAGGAGTGCAGAACTCAGTCAAAACATATCCAGC  1440
C T L V E V T E E E V E N S V K H I P S
TTGGCAACCGTGATCCTGGTGAAGACCATGATACGTAAACGCTCCTTTGGGAACCATTC  1500
L A T V I L V K T M I R K R S F G N P F
GAGGGCAGCGCGGGGAGGAACTCAGTGTGACGCGCTGGAACTTGCTCAGCAAGCAA  1560
E G S R R E E R S L S A P G N L L T K Q
GGCAGCAAGACAACTCCAGGGCAGCGCGCGCGCTGGGGGAGGAGGAAGTGTCT  1620
G S E D N L Q G T D P P V G E E E V L
TTGTGAAGGCGAGTCCCTGCGTGGAAAGTTGCTGGGCGCGCGCGCGCTCCCGCAC  1626
L *
GCATGATCCACTGCGGCGGAGGAGGATGGAGCCGAGTAACTGCCTGGATCGCCCG
ACCTCGCATGCGCGCGCGCTCGCTTGGGGGCTGCTGCACCGCTTTCATAG

```

B

```


humanCaMKK  β-1  421:DLITRLDKNPESRIVVPEIKLHPVWTRHGAELPSEDENCTLVEVEEVENSVKHIPS  480
humanCaMKK  β-2  421:-----  480
humanCaMKK  β-3  421:-----  480
humanCaMKK  β-3X  421:-----  441

*****
humanCaMKK  β-1  481:LATVILVKTMIKRSFGNPFEGSRREERSLSAPGNLLTKPKTRECESLSELKEARQRRQP  540
humanCaMKK  β-2  481:-----T  533
humanCaMKK  β-3  481:-----QGSEDNLQGTDPFPPVGEVEVL  540
humanCaMKK  β-3X  442:-----QGSEDNLQGTDPFPPVGEVEVL  497

humanCaMKK  β-1  541:PGHRPAPRGGGSALVRGSPCVESCWAPAGSPARMHPLRPEEAMEPE  588
humanCaMKK  β-2  541:L  541
humanCaMKK  β-3  541:L  541
humanCaMKK  β-3X  498:L  498

```

C



D




Fig. 4. Cloning and characterization of human CaM-KKβ-3. A: Nucleotide and deduced amino acid sequence of human CaM-KKβ-3. B: Comparison of C-terminal amino acid sequences of human CaM-KKβ-3, CaM-KKβ-3x, CaM-KKβ-1 and CaM-KKβ-2 [15]. Residues identical to the human CaM-KKβ-1 are indicated with a dash and gaps in the alignment are indicated as a dot. Asterisks indicate a putative regulatory domain including autoinhibitory and CaM-binding regions. C: CaM-KK activity of either recombinant CaM-KKβ-3 (0.32 μg/ml) or rat CaM-KKα (1.1 μg/ml) was measured in the presence of either 1 mM EGTA (–) or 1 mM CaCl₂/2 μM CaM (+) at 30°C for 5 min. Recombinant CaM-KKβ-3 (83 ng) and rat CaM-KKα (280 ng) were analyzed by CaM-overlay as described in Fig. 3 (inset). D: Activation of CaM-KIδ by CaM-KKβ-3 in transfected COS-7 cells. COS-7 cells were transfected with either 3 μg of empty vector (Mock) or 1.5 μg HA-CaM-KIδ-expressing vector with 1.5 μg empty pME18s vector or 1.5 μg CaM-KKβ-3-expressing vector. After 20 h incubation, the cells were further cultured in serum-free medium for 6 h and then treated with (+) or without (–) 1 μM ionomycin for 5 min. HA-CaM-KIδ was immunoprecipitated and then subjected to the protein kinase assay as described in Fig. 3B. Immunoprecipitated samples (1/5 vol.) were analyzed by CaM-overlay (inset). Arrow indicates HA-CaM-KIδ.

KI δ wild-type but not Thr180Ala mutant (Fig. 2C), indicating the presence of CaM-KI δ -activating kinase in the cells. We then further characterized the activation of CaM-KI δ in intact cells by transient transfection of HA-tagged CaM-KI δ into HeLa cells. In contrast to the parallel experiment using HA-CaM-KIV, whose kinase activity was lowered by the serum starvation and whose Ca²⁺/CaM-dependent activity was significantly (8-fold) enhanced by ionomycin stimulation (Fig. 3B), CaM-KI δ exhibited enhanced protein kinase activity even without ionomycin stimulation (Fig. 3A). This suggests that the CaM-KI δ pool in HeLa cells is maintained in a partially active form during the cell growth; however, ionomycin treatment further enhanced CaM-KI δ activity (1.5-fold). That its sustained activation involves the phosphorylation of its Thr180 residue is revealed by the assay with the Thr180Ala mutant, which exhibited a reduced protein kinase activity that was no longer induced by ionomycin stimulation (Fig. 3A). Furthermore, enhanced activity of HA-tagged CaM-KI δ in resting cells was significantly reduced by treatment of the cells with CaM-KK inhibitor, STO-609 after transfection (60–70% inhibitory rate, Fig. 3C). Next we examined the mechanism of this sustained activation of CaM-KI δ by using a Ca²⁺/CaM-independent mutant (residues 1–296) which lacks putative autoinhibitory and CaM-binding regions (Fig. 1B). Recombinant CaM-KI δ 1–296 phosphorylates the peptide substrate (syntide-2) in a complete Ca²⁺/CaM-independent manner (data not shown). Immunoprecipitated HA-CaM-KI δ 1–296 from transfected HeLa cells exhibited significantly increased autonomous activity (Fig. 3D) that was no longer induced by ionomycin stimulation unlike wild-type CaM-KI δ (Fig. 3A). This mutant CaM-KI δ was apparently fully activated in resting HeLa cells by endogenous CaM-KK which is active without Ca²⁺-mobilization or is activated at resting Ca²⁺ levels, since the increased autonomous activity of HA-CaM-KI δ 1–296 was inhibited by STO-609 treatment (75% inhibitory rate) either with or without ionomycin stimulation. Taken together these results, HeLa cells contain CaM-KK(s) that activate CaM-KI δ in both presence and absence of ionomycin stimulation and the sustained activation of CaM-KI δ is contributed at least in part by Ca²⁺-independent CaM-KK.

In order to identify the CaM-KK that activates CaM-KI δ in HeLa cells, we performed an RT-PCR that specifically amplifies CaM-KK isoforms using cDNA prepared from HeLa cells as a template. As a result, we could detect CaM-KK α in HeLa cells but two recently cloned isoforms of CaM-KK β , CaM-KK β -1 and β -2 [15] have not been detected (data not shown). However, we have isolated a novel CaM-KK β isoforms from HeLa cells by RT-PCR using specific 5'-UTR and 3'-UTR sequences in CaM-KK β -1 as the PCR primers and obtained two full-length clones. The 1.8 kb clone, as shown in Fig. 4A,B, encodes a 541 amino acid protein that lacks exon 16 [15] and therefore has a C-terminal sequence that is distinct from that of CaM-KK β -1 and β -2 isoforms. We therefore termed this novel splice isoform of CaM-KK β as CaM-KK β -3. The nucleotide sequence of 1.7 kb clone revealed that the clone is identical with CaM-KK β -3 except in that it also lacks exon 14 [15], which encodes the C-terminus of the catalytic domain as well as N-terminal half of the regulatory domain (Leu442–Val484, [14]) (Fig. 4B). We denoted this splice isoform as CaM-KK β -3x. Isolation of the full-length cDNAs of CaM-KK β -3 and CaM-KK β -3x in this study is in good agreement with a recent finding based

on RT-PCR amplification of partial cDNA fragments of CaM-KK β , suggesting that the additional forms of CaM-KK β transcripts are generated through alternative splicing of the internal exons 14 and/or 16 [15]. RT-PCR analysis indicated that both are expressed in all human peripheral tissues we tested (data not shown) indicating that CaM-KK β -3 is a non-neuronal CaM-KK and could be a candidate of CaM-KI δ activator.

Next we examined the activity and the Ca²⁺/CaM-dependency of CaM-KK β -3 by using GST–CaM-KI 1–293 K49E as a substrate (Fig. 4C). Whereas CaM-KK activity of rat CaM-KK α is completely dependent on Ca²⁺/CaM, recombinant CaM-KK β -3 showed enhanced autonomous activity (80% of total activity). This is consistent with a previous observation indicating an enhanced autonomous activity of rat CaM-KK β [14]. Although CaM-KK β -3 exhibited an increased autonomous activity, activation of CaM-KI δ by CaM-KK β -3 in vitro was in a completely Ca²⁺/CaM-dependent manner (data not shown) as well as CaM-KK α (Fig. 2A), suggesting that the Thr180 in CaM-KI δ can not be accessed and phosphorylated by CaM-KK β -3 without binding of Ca²⁺/CaM to CaM-KI δ , which is analogous to CaM-KI activation in vitro [21,22].

Finally, we attempted to reconstitute CaM-KK β -3/CaM-KI δ cascade in transfected COS-7 cells (Fig. 4D). Similar to what observed in transfected HeLa cells, HA-CaM-KI δ is maintained as an active form in transfected COS-7 cells even without ionomycin stimulation. The addition of ionomycin raised (~1.5-fold) CaM-KI δ activity indicating that COS-7 cells contain CaM-KI δ -activating activity. When the COS-7 cells were cotransfected with vectors expressing HA-CaM-KI δ and CaM-KK β -3, CaM-KI δ activity was raised to the level of the ionomycin-induced CaM-KI δ activity in single transfected cells. This indicates that CaM-KK β -3 is capable of phosphorylating and activating CaM-KI δ in intact cells.

In summary, we have identified and cloned a novel human member of the CaM-KI subfamily that we have denoted as CaM-KI δ . Here we have shown that CaM-KI δ is activated by CaM-KK through phosphorylation of Thr180 both in vitro and in vivo. We observed the sustained activation of CaM-KI δ in intact cells, which is quite unlike the CaM-KIV activation. Based on our data, a part of CaM-KI δ could be constitutively activated at resting Ca²⁺ levels in the cells through phosphorylation of Thr180 by CaM-KK. This is also consistent with our finding that resting HeLa cells contain CaM-KI δ -activating activity and CaM-KK β -3 exhibited enhanced Ca²⁺/CaM-independent activity. Taken together, CaM-KK/CaM-KI δ cascade is functionally operated in HeLa cells and apparently involved in the sustained activation of CaM-KI δ .

References

- [1] Soderling, T.R. (1999) Trends Biochem. Sci. 24, 232–236.
- [2] Corcoran, E.E. and Means, A.R. (2001) J. Biol. Chem. 276, 2975–2978.
- [3] Tokumitsu, H., Enslin, H. and Soderling, T.R. (1995) J. Biol. Chem. 270, 19320–19324.
- [4] Edelman, A.M., Mitchelhill, K.I., Selbert, M.A., Anderson, K.A., Hook, S.S., Stapleton, D., Goldstein, E.G., Means, A.R. and Kemp, B.E. (1996) J. Biol. Chem. 271, 10806–10810.
- [5] Kitani, T., Okuno, S. and Fujisawa, H. (1997) J. Biochem. (Tokyo) 122, 243–250.
- [6] Anderson, K.A., Means, R.L., Huang, Q.H., Kemp, B.E., Gold-

- stein, E.G., Selbert, M.A., Edelman, A.M., Freneau, R.T. and Means, A.R. (1998) *J. Biol. Chem.* 273, 31880–31889.
- [7] Tokumitsu, H., Takahashi, N., Eto, K., Yano, S., Soderling, T.R. and Muramatsu, M. (1999) *J. Biol. Chem.* 274, 16073–16076.
- [8] Joseph, J.D. and Means, A.R. (2000) *J. Biol. Chem.* 275, 38230–38238.
- [9] Alleta, J.M., Selbert, M.A., Nairn, A.C. and Edelman, A.M. (1996) *J. Biol. Chem.* 271, 20930–20934.
- [10] Eto, K., Takahashi, N., Kimura, Y., Masuho, Y., Arai, K., Muramatsu, M. and Tokumitsu, H. (1999) *J. Biol. Chem.* 274, 22556–22562.
- [11] Kimura, Y., Corcoran, E.E., Eto, K., Gengyo-Ando, K., Muramatsu, M., Kobayashi, R., Freedman, J.H., Mitani, S., Hagiwara, M., Means, A.R. and Tokumitsu, H. (2002) *EMBO Rep.* 3, 962–966.
- [12] Suizu, F., Fukuta, Y., Ueda, K., Iwasaki, T., Tokumitsu, H. and Hosoya, H. (2002) *Biochem. J.* 367, 335–345.
- [13] Murata-Hori, M., Suizu, F., Iwasaki, T., Kikuchi, A. and Hosoya, H. (1999) *FEBS Lett.* 451, 81–84.
- [14] Tokumitsu, H., Iwabu, M., Ishikawa, Y. and Kobayashi, R. (2001) *Biochemistry* 40, 13925–13932.
- [15] Hsu, L.S., Chen, G.D., Lee, L.S., Chi, C.W., Cheng, J.F. and Chen, J.Y. (2001) *J. Biol. Chem.* 276, 31113–31123.
- [16] Tokumitsu, H., Brickey, D.A., Gold, J., Hidaka, H., Sikela, J. and Soderling, T.R. (1994) *J. Biol. Chem.* 269, 28640–28647.
- [17] Tokumitsu, H., Inuzuka, H., Ishikawa, Y., Ikeda, M., Saji, I. and Kobayashi, R. (2002) *J. Biol. Chem.* 277, 15813–15818.
- [18] Tokumitsu, H., Inuzuka, H., Ishikawa, Y. and Kobayashi, R. (2003) *J. Biol. Chem.* 278, 10908–10913.
- [19] Tokumitsu, H., Muramatsu, M., Ikura, M. and Kobayashi, R. (2000) *J. Biol. Chem.* 275, 20090–20095.
- [20] Verploegen, S., Lammers, J.W., Koenderman, L. and Coffey, P.J. (2000) *Blood* 96, 3215–3223.
- [21] Matsushita, M. and Nairn, A.C. (1998) *J. Biol. Chem.* 273, 21473–21481.
- [22] Haribabu, B., Hook, S.S., Selbert, M.A., Goldstein, E.G., Tomhave, E.D., Edelman, A.M., Synderman, R. and Means, A.R. (1995) *EMBO J.* 14, 3679–3686.